<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04794569</url>
  </required_header>
  <id_info>
    <org_study_id>3315</org_study_id>
    <nct_id>NCT04794569</nct_id>
  </id_info>
  <brief_title>Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome</brief_title>
  <acronym>TILE</acronym>
  <official_title>Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome Phase IV Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sunnybrook Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The TILE pilot study will be a multicenter, open-label, assessor-blinded RCT (randomized&#xD;
      control trial) comparing extended LMWH (Low Molecular Weight Heparin) vs. DOAC (Direct Oral&#xD;
      Anticoagulants) to PTS (prevent post thrombotic syndrome) in patients with DVT (Deep Vein&#xD;
      Thrombosis).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TILE pilot study will investigate the magnitude of difference in effectiveness between&#xD;
      LMWH (low molecular weight heparin, tinzaparin) plus DOAC (Direct Oral Anticoagulants,&#xD;
      rivaroxaban) vs. DOAC alone to determine the sample size and assess feasibility for a larger&#xD;
      study assessing the effectiveness of an initial 3-week lead-in course of LMWH (tinzaparin)&#xD;
      compared to DOAC alone (rivaroxaban) in patients with proximal DVT (Deep Vein Thrombosis) at&#xD;
      high risk of developing PTS (Post-Thrombotic Syndrome). PTS is a frequent, costly and&#xD;
      burdensome complication of DVT, especially for patients with iliac or femoral vein DVT who&#xD;
      have a high risk of developing PTS and severe PTS. Anticoagulant therapy appears to influence&#xD;
      this risk, with a higher frequency of PTS in patients with DVT who receive suboptimal&#xD;
      treatment with a VKA (Vitamin K Antagonist). DOAC are expected to avoid this and other&#xD;
      limitations of VKA therapy and have become the standard of care for patients with DVT.&#xD;
      Extended treatment of DVT with LMWH, by providing more effective anticoagulation and by&#xD;
      reducing inflammation, appears to restore venous patency and reduce venous reflux compared to&#xD;
      VKA and probably to DOAC. Extended treatment of DVT with LMWH, therefore, has the potential&#xD;
      to reduce PTS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Patients will be instructed not to disclose their treatment to PTS assessors</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>PTS at 6 months</measure>
    <time_frame>6 months post randomization</time_frame>
    <description>Proportion of patients with PTS at 6 months using the Villalta scale. PTS will be diagnosed using the Villalta scale. This clinical scale is the recommended standard to diagnose PTS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Main feasibility</measure>
    <time_frame>3 months post randomization</time_frame>
    <description>Main feasibility outcomes: a. Proportion of eligible patients, among patients screened b. Proportion of recruited patients, among patients who are eligible c. Proportion of patients who are compliant with tinzaparin, among recruited patients assigned to tinzaparin arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PTS severity</measure>
    <time_frame>6 months post randomization</time_frame>
    <description>The Villalta scale will be used to grade the severity of PTS (mild, moderate, severe) at 6 months post randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Villalta score at 10 days</measure>
    <time_frame>10 days post randomization</time_frame>
    <description>Villalta score at 10 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DVT-related leg pain</measure>
    <time_frame>Two time points: at 10 days and at 3 months post randomization</time_frame>
    <description>DVT-related leg pain will be assessed using an 11-point Likert rating scale (0 no pain, 10, worst possible pain, during the last 24 hours). This relates to sub-acute DVT pain and not a pain that could have been caused by LMWH injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Improvement</measure>
    <time_frame>Two time points: at 10 days and at 3 months post randomization</time_frame>
    <description>Assessing Patient's global improvement using the Patient's global improvement scale (On a scale of 1 to 7, where 1 is extremely improved and 7 is extremely deteriorated).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's satisfaction with treatment</measure>
    <time_frame>Two time points: at 3 weeks and at 6 months post randomization</time_frame>
    <description>Patient's satisfaction with treatment and patient's global improvement will be assessed using a 7-point Likert visual analog scale questionnaire (1 = extremely satisfied to 7 = extremely dissatisfied).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL (Quality of Life) score - SF-36</measure>
    <time_frame>Three time points: at 3 weeks and at 6 months post randomization</time_frame>
    <description>Generic QOL will be measured using Short-Form Health Survey-36 (SF-36) instrument. Physical and Mental Component Summary scores reflect physical and mental health status, respectively. To only take into account change in QOL related to DVT, at the 3 week visit, we will change the first sentence (i.e. stem) of the SF-36 questionnaire from 'over the past 4 weeks' to 'over the past 3 weeks'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL (Quality of Life) score - VEINES-QOL</measure>
    <time_frame>Three time points: at 3 weeks and at 6 months post randomization</time_frame>
    <description>Venous disease-specific QOL will be assessed with VEINES-QOL, a 25-item self-completed measure. To only take into account change in QOL related to DVT, at the 3 week visit, we will change the first sentence (i.e. stem) of the VEINES-QOL questionnaire from 'over the past 4 weeks' to 'over the past 3 weeks'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAEs</measure>
    <time_frame>baseline to 6 months post randomization</time_frame>
    <description>Serious adverse events (SAE) will be defined as per the Health Canada definition. SAEs will be reported as required by local regulations, with copies sent to Health Canada, Therapeutic Product Directorate (Ottawa), Leo Pharma (maker of tinzaparin) and Bayer (maker of rivaroxaban). SAEs from baseline to 3 weeks and from 3 weeks to 6 months, including recurrent DVT, PE (Pulmonary Embolism), major bleeding and clinically relevant non-major bleeding, death will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of lost to follow-up</measure>
    <time_frame>6 months post randomization</time_frame>
    <description>The number of patients randomized that do not attend (in person or over the phone) the 6-month follow-up visit; Patients who withdraw consent are not considered as lost to follow-up.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health Services Research Issues</measure>
    <time_frame>6 months post randomization</time_frame>
    <description>QOL analyses will be conducted in the pilot study, as it is relevant to comprehensively evaluate chronic burdensome conditions like PTS. Utilities for health states will be derived from QOL measurements</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Post Thrombotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Tinzaparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>initial 3-week lead-in course of low molecular weight heparin (tinzaparin 175 units/Kg sc daily) followed by a direct oral anticoagulant (rivaroxaban 20mg po daily) for at least 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Direct oral anticoagulant only (rivaroxaban 15mg po BID for 3 weeks followed by rivaroxaban 20mg po daily ) for at least 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tinzaparin</intervention_name>
    <description>low molecular weight heparin</description>
    <arm_group_label>Tinzaparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>direct oral anticoagulant</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Patients with objectively confirmed acute (i.e. onset of symptoms &lt;10 days) symptomatic&#xD;
        iliac or common femoral DVT (DVT diagnosis will be made with a Compression Ultrasound (CUS)&#xD;
        according to standardized consensus criteria)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 18 years&#xD;
&#xD;
          2. History of ipsilateral DVT (distal and/or proximal)&#xD;
&#xD;
          3. Active cancer&#xD;
&#xD;
          4. Thrombolysis or other invasive early thrombus removal technique to treat DVT or PE&#xD;
&#xD;
          5. Pregnant or breast feeding&#xD;
&#xD;
          6. Impaired renal function (creatinine clearance &lt; 30 ml/min according to Cockcroft-Gault&#xD;
             formula)&#xD;
&#xD;
          7. Concomitant use of drugs that interact with rivaroxaban (i.e. keto- or itraconazole,&#xD;
             ritonavir)&#xD;
&#xD;
          8. Allergy or hypersensitivity to heparin or rivaroxaban, including heparin induced&#xD;
             thrombocytopenia&#xD;
&#xD;
          9. Anticoagulant therapy contraindicated because of presence of active bleeding or&#xD;
             condition with high risk of bleeding (e.g. peptic ulcer, other)&#xD;
&#xD;
         10. Thrombocytopenia (platelet count &lt; 100 x 109/L)&#xD;
&#xD;
         11. Liver disease (including Child-Pugh Class B and Class C) associated with coagulopathy&#xD;
&#xD;
         12. Body weight &gt; 120 kg or &lt; 40 kg&#xD;
&#xD;
         13. Need for treatment with daily NSAIDs or antiplatelet agent (ibuprofen &lt; 1200 mg/day,&#xD;
             aspirin ≤ 160 mg/day or clopidogrel ≤ 75 mg/day are permitted)&#xD;
&#xD;
         14. Treatment with therapeutic doses of anticoagulants for &gt; 48 hours (3 injections of&#xD;
             LMWH if twice daily therapeutic LMWH used, 2 injections of LMWH if once daily&#xD;
             therapeutic LMWH used, 3 doses of twice daily 15 mg of rivaroxaban)&#xD;
&#xD;
         15. Mechanical heart valve&#xD;
&#xD;
         16. Life expectancy &lt; 1 year&#xD;
&#xD;
         17. Unable or unwilling to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Philippe Galanaud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre (Toronto, Ontario, Canada)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan R Kahn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish General Hospital (Montreal, Quebec, Canada)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Philippe Galanaud, MD</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>3056</phone_ext>
    <email>Jean-Philippe.Galanaud@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sonya Mergler</last_name>
    <phone>(416) 480-5627</phone>
    <email>tile@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Sam Schulman, MD</last_name>
      <phone>905-527-4322</phone>
      <phone_ext>44479</phone_ext>
      <email>schulms@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Zondag</last_name>
      <phone>905-527-4322</phone>
      <phone_ext>44807</phone_ext>
      <email>zondag@hhsc.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Philippe Galanaud, MD</last_name>
      <phone>416-480-5953</phone>
      <email>Jean-Philippe.Galanaud@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan Sasitharan</last_name>
      <email>jonathan.sasitharan@sri.utoronto.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Makedonov I, Kahn SR, Galanaud JP. Prevention and Management of the Post-Thrombotic Syndrome. J Clin Med. 2020 Mar 27;9(4). pii: E923. doi: 10.3390/jcm9040923. Review.</citation>
    <PMID>32230912</PMID>
  </reference>
  <reference>
    <citation>Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA, Gupta DK, Prandoni P, Vedantham S, Walsh ME, Weitz JI; American Heart Association Council on Peripheral Vascular Disease, Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014 Oct 28;130(18):1636-61. doi: 10.1161/CIR.0000000000000130. Epub 2014 Sep 22. Erratum in: Circulation. 2015 Feb 24;131(8):e359.</citation>
    <PMID>25246013</PMID>
  </reference>
  <reference>
    <citation>Hull RD, Townshend G. Long-term treatment of deep-vein thrombosis with low-molecular-weight heparin: an update of the evidence. Thromb Haemost. 2013 Jul;110(1):14-22. doi: 10.1160/TH12-12-0931. Epub 2013 Apr 25. Review.</citation>
    <PMID>23615656</PMID>
  </reference>
  <reference>
    <citation>Kahn SR, Partsch H, Vedantham S, Prandoni P, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. J Thromb Haemost. 2009 May;7(5):879-83. doi: 10.1111/j.1538-7836.2009.03294.x. Epub 2009 Jan 19.</citation>
    <PMID>19175497</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tinzaparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Postthrombotic Syndrome</mesh_term>
    <mesh_term>Postphlebitic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

